Jim Cramer recommends buying TG Therapeutics (TGTX) stock for its leadership and potential
- Jim Cramer recommended buying TG Therapeutics, Inc. (TGTX) stock, praising the company’s leadership and potential.
- TG Therapeutics, Inc. (TGTX) focuses on developing therapies for B-cell mediated diseases, including multiple sclerosis. ClearBridge Investments added TGTX to its investment portfolio in Q4 2024.
- ClearBridge Investments sees potential in TG Therapeutics, Inc. (TGTX) but believes other AI stocks offer better upside with less risk.
- Explore more stock insights with articles on the Best and Worst Dow Stocks and 10 Unstoppable Stocks. No disclosures mentioned in the article.
Read more at Yahoo Finance: “You Should Buy the Stock”